Quantum Genomics

Quantum Genomics was founded in 2007 with a mission to develop first-in-class, centrally-acting antihypertensives based on inhibition of brain aminopeptidase A (APA). Its primary achievement was advancing its lead candidate, firibastat, into Phase IIb/III clinical trials for resistant hypertension and Phase II for heart failure. The company's strategy was to address significant unmet needs in cardiovascular diseases through a novel mechanism of action complementary to existing therapies. However, the company appears to be in a state of crisis, with its public communications halted and its website displaying a message indicating severe financial insolvency.

A proprietary platform focused on developing orally-administered, brain-penetrant small molecule inhibitors of aminopeptidase A (APA), a key enzyme in the brain renin-angiotensin system, to modulate central sympathetic outflow and vasopressin release.

Firibastat was a first-in-class agent with no direct mechanism-of-action competitors. However, its clinical failure rendered it non-competitive against both established generic antihypertensives and newer, validated therapies for resistant hypertension, such as device-based renal denervation and the recently approved drug aprocitentan.